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Cardiotocography (CTG) has a high sensitivity but only a limited
speciﬁcity in predicting fetal hypoxia/acidosis [1]. In other words, a
normal CTG is reassuring regarding the state of fetal oxygenation as
hypoxia/acidosis is generally restricted to cases with suspicious or
pathological patterns (see the deﬁnitions given in the CTG chapter
[1]). However, a large number of fetuses with the latter patterns will
not have clinically important hypoxia/acidosis [2,3]. To reduce such
false positive cases and unnecessary medical interventions, adjunctive
technologies have been proposed to further assess fetal oxygenation.
These technologies should indicate intervention at an early stage
of evolving fetal hypoxia/acidosis to prevent rather than to predict
poor newborn outcome. Several adjunctive technologies have been
developed over the last decades, including fetal blood sampling
(FBS), continuous pH and lactate monitoring, fetal stimulation, pulse
oximetry, and ST waveform analysis, and some of these have been suc-
cessfully established.
Continuous fetal pH monitoring was developed in the 1970s;
however, several technical difﬁculties arose, particularly surrounding
the use of glass electrodes that could break in the fetal scalp, and the
technique was subsequently abandoned. Fetal pulse oximetry was
developed in the 1990s, but the commercialization of electrodes has
subsequently been discontinued. A systematic review of four trials☆ Developed by the FIGO Safe Motherhood and Newborn Health Committee;
coordinated by Diogo Ayres-de-Campos.
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ference in the overall cesarean delivery rate (relative risk [RR] 0.99; 95%
CI, 0.86–1.13), while adverse fetal outcomes were rare in both groups
[4]. The present chapter focuses on the adjunctive technologies current-
ly available for intrapartum fetal monitoring.
2. Fetal blood sampling for pH and lactate measurements
FBS during laborwasﬁrst described in 1962 [5] and is currently used
for assessment of fetal blood gases and/or lactate. Studies in fetal mon-
keys showed a good correlation of acid–base parameters between scalp
and carotid blood [6], and human data have shown similar correlations
between pH and lactate values obtained in scalp blood and those re-
corded shortly after birth in the umbilical artery and vein [7–11]. How-
ever, correlation of these values with newborn outcome depends on the
time interval between scalp sampling and birth [12]. It has been argued
that fetal capillary blood is likely to be affected by the redistribution of
circulation occurring during fetal hypoxemia, and therefore it may not
adequately represent the central circulation [13]. The opposite argu-
ment is that this aspect favors FBS because intrapartum fetalmonitoring
aims to identify fetuses in the early rather than in the late process of
hypoxia.
2.1. Indications
FBS may be used in cases of suspicious or pathological CTG [1].
When pathological CTGs indicate a severe and acute event [1], immedi-
ate action should be taken and FBS is not advised as it would cause fur-
ther delay.
2.2. Technique
To perform FBS a disposable or reusable FBS set can be used. It is nec-
essary for themembranes to be ruptured and cervical dilation should be
at least 3 cm. A vaginal examination needs to be performed prior to the
procedure to assess the nature and position of the presenting part. The
technique has similar contraindications to those of the fetal electrode:
active genital herpes infection, women seropositive to hepatitis B, C, D,
E, or to HIV, suspected fetal blood disorders, uncertainty about the pre-
senting part, or when artiﬁcial rupture of membranes is inappropriate.
An amnioscope (the diameter of which can vary according to cervical
dilation) is inserted into the vagina and the lighting equipment isynecology and Obstetrics.
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is dried using small swabs and a thin layer of parafﬁn is applied to the
presenting part so that blood will form in a large drop and not spread
over the skin, thus causing loss of carbon dioxide by diffusion. The inci-
sion on the fetal skin should not exceed 2 mm. After a blood drop has
formed it is collected in a heparin-coated capillary. Following collection
the incision site is inspected for persistent bleeding, which can usually
be resolved with continuous pressure. In about 10% of attempts no pH
information is obtained owing to blood clotting within the capillary, in-
sufﬁcient blood obtained, air bubbles inside the capillary, or a blood gas
measurer that is calibrating at the time the sample needs to be analyzed.
The failure rate when lactate analysis is performed is lower, at about
1.5% [14,15]. This is because for lactate analysis, approximately 5 μL is
needed as compared with 50 μL that is required for blood gas assess-
ment [15–17].
2.3. Interpretation of results
In three studies conducted in the 1960s, scalp pH values were eval-
uated in a total of 180womenwith normal CTG tracings [18–20]. During
the ﬁrst stage of labor the lowest reported values were between 7.18
and 7.21. Based on these data, fetal acidosis during the ﬁrst stage of
labor was deﬁned as a pH less than 7.20. This was later conﬁrmed in a
larger study including 306 fetuses [21].
In a large randomized controlled trial (RCT) comparing scalp pH and
lactate measurements, the rate of operative deliveries was identical
when cut-off values for intervention were set at pH less than 7.21 and
lactate greater than 4.8 mmol/L; the latter value is commonly used to
deﬁne the need for intervention [17]. However, cut-off values for lactate
need to consider the apparatus used for measurement; the 4.8 mmol/L
value was the only one to have been evaluated in this manner and
was established with the Lactate Pro meter (Arkray, Kyoto, Japan). Fur-
ther studies should also consider subgroup analysis to establish cut-off
values by gestational age and stage of labor [14]. The interpretation of
pH and lactate values is shown in Table 1 [22].
Intervention is indicated in cases of pH less than 7.20 or lactate
greater than 4.8 mmol/L, and this should result in actions toward nor-
malization of the CTG pattern or rapid delivery [1]. When the pH is be-
tween 7.20 and 7.25 or lactate is between 4.2 and 4.8 mmol/L [23],
measures should be taken to improve fetal oxygenation. If the CTG
abnormality persists or the pattern worsens, FBS should be repeated
within 20–30 minutes. With a normal pH or lactate value no further ac-
tion is usually required, but if the CTG remains grossly abnormal, FBS
should be repeated within the next 60 minutes. A normal lactate mea-
surement is strongly predictive of absent hypoxia/acidosis when per-
formed in the last hour of labor [17,24]. With a continuously abnormal
CTG pattern—even after three or more normal FBS results have been
obtained—the fetus can still be safely delivered vaginally in about 60%
of cases [25].When three adequate FBS results have been obtained, con-
sideration of further testing is rarely needed.
2.4. Does FBS improve fetal outcome?
There is uncertainty about whether the use of FBS as an adjunct to
CTG—measuring either pH or lactate—improves neonatal outcome and
reduces intervention rates. The ﬁrst meta-analysis of RCTs comparing
continuous CTG with intermittent auscultation for intrapartum fetalTable 1
Interpretation of fetal blood sampling results regarding pH and lactate values.
pH Lactate (mmol/L) Interpretation
N7.25 b4.2 Normal
7.20–7.25 4.2–4.8 Intermediate
b7.20 N4.8 Abnormalmonitoring, when analyzing the three trials in which FBS was not
used as an adjunctive technology, found an almost three-fold increase
in cesarean delivery rates in the CTG arm [26]. In the six trials in
which FBS was used as an adjunct to CTG (CTG+ FBS) the cesarean de-
livery rate was only 30% higher than in the intermittent auscultation
arm, while neonatal seizures were reduced by 50%. In the only trial in
which CTG with and without FBS were directly compared, cesarean de-
livery rates were 11% and 18%, respectively, but this difference was not
statistically signiﬁcant [27].
A 2013 Cochrane Review based on seven trials with FBS as an ad-
junctive technology and ﬁve with CTG only, found a relative risk of
1.34 for cesarean delivery in the former and 1.63 in the latter, when
compared with intermittent auscultation [28]. Instrumental vaginal de-
liveries were somewhat higher in the CTG + FBS trials and acidosis in
cord blood somewhat lower. A systematic review of the studies directly
evaluating this technique concluded that, based on heterogeneous data
of modest quality with somewhat inconsistent results, CTG + FBS “can
provide additional information on fetal well-being” and “can reduce the
risk of operative delivery” [29].
The National Institute of Clinical Excellence guidelines of 2014
consider that use of FBS “may help to reduce the need for further,
more serious interventions” [22]. The guidelines of the Society of Obste-
tricians and Gynaecologists of Canada recommend FBS in association
with CTG for uninterpretable or nonreassuring tracings, but consider
the level of evidence to be moderate [30].
Altogether these data suggest that CTG + FBS results in a reduction
in cesarean deliveries when compared with CTG alone. However, more
than 50 years after its introduction, a high quality RCT is still needed to
evaluate the effect of CTG with or without FBS on perinatal outcomes
and intervention rates.
2.5. Limitations and risks
FBS use is mainly limited to central and northern Europe. The reason
for the low global uptake of FBS may include that it is not particularly
patient- or user-friendly. Moreover, it is time-consuming, with a medi-
an interval of 18 minutes between the decision to perform and the re-
sult [31]. This interval is signiﬁcantly shorter when using point-of-care
devices, with a median sampling interval of 2 minutes for lactate analy-
sis usingmicro-volumemeters [16]. A survey from Sweden published in
2014 concluded that FBSwaswell tolerated by laboringwomen, and cli-
nicians did not consider it difﬁcult to perform [32]. Given the dynamic
nature of fetal hypoxia/acidosis during labor, the information provided
by FBS quickly becomes outdated, requiring repetitions of the method.
It is also difﬁcult to perform in early labor and carries a small risk of in-
fection and bleeding. Moreover, it requires laboratory support to evalu-
ate blood gases and lactate, although bedside techniques have largely
overcome this [33]. In the USA, FBS has been virtually abandoned
following a paper suggesting that CTG, when properly interpreted,
may be equal or superior in the prediction of both normal and adverse
outcomes [34].
3. Fetal scalp stimulation
Fetal scalp stimulation (FSS) involves stimulating the fetal scalp by
rubbing it with the examiner’s ﬁngers or using forceps to clasp the
fetal skin, or alternatively using vibroacoustic stimulation applied to
the mother’s abdomen. Digital scalp stimulation is the most widely
used as it is the easiest to perform, less invasive, and appears to have a
similar predictive value for fetal hypoxia/acidosis to the other alterna-
tives [35]. The main purpose of FSS is to evaluate fetuses showing
reduced variability on CTG to distinguish between deep sleep and
hypoxia/acidosis. It is of questionable value in other patterns. Observa-
tional studies have shown that when FSS leads to the appearance of
an acceleration and subsequent normalization of the fetal heart
pattern, this should be regarded as a reassuring feature, with a negative
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When FSS does not elicit the appearance of accelerations, or when
accelerations occur but continued reduced variability ensues [35], the
positive predictive value for fetal hypoxia/acidosis is limited. In these
situations continued monitoring and additional tests are necessary. It
has been reported that in settings were FBS is used, FSS may reduce its
need by about 50% [36].
4. Combined cardiotocographic–electrocardiographic monitoring
Combined cardiotocographic-electrocardiographic (CTG + ST)
monitoring was commercialized in 2000 and associates continuous in-
ternal CTG monitoring with analysis of the fetal electrocardiogram ST
segment morphology. The monitor evaluates 30 heart cycles to con-
struct an average electrocardiographic signal that is then used for mor-
phologic analysis of the ST segment (STAN; Neoventa, Gothenburg,
Sweden). Information is obtained on the amplitude of the T-wave in re-
lation to the QRS complex (T/QRS ratio) and on the shape of ST seg-
ments, which when showing an important part below the baseline are
named grade 2 and 3 biphasic STs. Extensive animal experiments per-
formed in the 1970s showed that during hypoxia, ST segment changes
precede the signs of failing cardiovascular function [37,38]. Themonitor
provides automatic warnings called “ST events”when relevant changes
are detected in ST segment analysis. The theoretical advantages of
CTG+ ST monitoring over FBS are its less invasive nature, an easier ap-
plicability during early labor, and the display of continuous information.
4.1. Indications
CTG+STmonitoringmay be used to provide additional information
about cardiac oxygenation in cases of suspicious or pathological CTG
tracings [1]. When reduced variability and absent accelerations are al-
ready present on CTG, ST information cannot be reliably used to indicate
fetal hypoxia/acidosis (see below). With pathological CTG indicating a
severe and acute event [1], immediate action should be undertaken
with or without the occurrence of ST events.
4.2. Technique
A fetal electrode is necessary to acquire continuous CTG+ST signals.
Therefore, the technique has similar contraindications to internal CTG
monitoring [1] and to FBS (see section above on the contraindications
to FBS). The ST technology has not been extensively evaluated for gesta-
tional ages below 36 weeks.
4.3. Interpretation of results
Tracing interpretation needs to take into account the CTG pattern
and the degree of ST changes. Speciﬁc guidelines were developed
for CTG interpretation, inspired by the original FIGO guidelines of
1987, together with speciﬁc CTG + ST criteria for taking clinical action
[39]. The system’s automatic warnings of ST events only occur when it
detects changes in ECG morphology when compared with a previously
existing state, and these changesmay not be detectable if ECGmorphol-
ogy is already abnormal at the start of recording. Therefore, a “reactive
CTG” (i.e. one showing normal variability and accelerations) or a normal
FBS need to be documented at the start of monitoring for safe use of ST
information. If FBS is not available, conservative measures to improve
the CTG pattern can be considered (turning the laboring woman on
her side, stopping oxytocin, acute tocolysis, reverting maternal hypo-
tension if this was documented) before starting CTG + ST monitoring.
When the CTG is normal, ST events should be ignored as in this set-
ting they do not indicate fetal hypoxia/acidosis. A few cases have been
described in which CTG tracings have gradually changed from normal
to pathological, without the appearance of ST events [40]. For this
reason, any abnormal CTG lasting more than 60 minutes, or less if theCTG pattern deteriorates rapidly, requires assessment by a senior obste-
tricianwhether or not ST events occur.With a CTG showing persistently
reduced variability or a pattern indicating a severe and acute hypoxic
event, intervention is always required irrespective of ST data [39].
4.4. Does CTG + ST monitoring improve fetal outcome?
Six RCTs were published that compared CTG + ST monitoring with
isolated CTG, for a total of more than 26 000 enrolled women [41–48].
Theﬁrst trial used an earlier version of the technology, theﬁrstﬁve trials
were conducted in Europe using FBS as an adjunctive technique, and the
most recent trial was performed in the USA, where a simpliﬁed three-
tier CTG classiﬁcation was used and FBS was not available. Several
meta-analyses of the ﬁrst ﬁve RCTs have been performed, but doubts re-
main as to whether the ﬁrst trial should be included owing to the dif-
ferent version of the technology [49–53], and whether a more recent
study [53] should be included because its entry criteria contradict the
established CTG + ST guidelines.
All ﬁve European RCTs point to a reduction of FBS use of about 40% in
the CTG+ ST arm. Newborn metabolic acidosis was signiﬁcantly lower
in the CTG + ST arm in one of the larger trials, a similar trend was
observed in two other large studies, and an opposite trend was seen
in the two smaller trials. Operative deliveries (instrumental vaginal
deliveries and cesarean deliveries) were signiﬁcantly lower in the
CTG + ST arm in one large study, showed a similar trend in another
large study, and showed no difference in the remaining three studies.
The 26-center USA trial enrolling 11 108 participants showed no differ-
ences in operative delivery or adverse neonatal outcome between the
two arms [48].
A few centers have published data on neonatal outcome in the years
following the introduction of the CTG + ST technology together with
structured CTG training, and have reported progressive declines in the
incidence of metabolic acidosis, with stable or decreasing intervention
rates [54–56]. A causal relationship with the CTG + ST technology or
with structured CTG training has not been established, but these unique
outcomes deserve close attention. The importance of training and of
prioritizing of the labor ward may have been underestimated. The ST
technique is still relatively new and its guidelines were developed em-
pirically. Further research is needed to evaluatewhether changingman-
agement guidelines will improve the performance of the technique.
Recently it has been suggested that biphasic STs do not add to the diag-
nostic value of the technique [57].
4.5. Limitations and risks
Clinical use of CTG + ST requires a relatively complex educational
process. A CTG with normal variability and accelerations or a normal
FBS is required at the start of monitoring for a conﬁdent evaluation of
ST data, but even then hypoxia/acidosis can rarely develop during
labor without the occurrence of ST events. Finally, ST events have
been reported in about 50% of normally oxygenated fetuses, but only
in 16%were they associatedwith abnormal CTG patternswarranting in-
tervention according to the STAN guidelines [58].
5. Computer analysis of fetal monitoring signals
Computer analysis of CTGs was developed to overcome the poor
interobserver agreement on tracing interpretation and to provide an
objective evaluation of some CTG features that are difﬁcult to assess
visually, such as variability [1]. Over the last two decades, a small num-
ber of systems for computer analysis of intrapartum fetal monitoring
signals have been commercialized, all in association with fetal central
monitoring stations [59]: IntelliSpace Perinatal, incorporating the
former OB TraceVue (Philips Healthcare, Eindhoven, Netherlands);
Omniview-SisPorto (Speculum, Lisbon, Portugal) [60]; PeriCALM
(PeriGen, Cranbury, NJ, USA) [61]; INFANT (K2 Medical Systems,
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Chalfont, UK and Trium Analysis Online GmbH, Munich, Germany).
These systems incorporate real-time visual and sound alerts
for healthcare professionals based on the results of computer analysis
of CTG or combined CTG + ST signals [60]. These alerts aim to raise
attention to speciﬁc ﬁndings and prompt tracing re-evaluation, with
subsequent action if considered necessary. All systems use relatively
similar color-coding for alerts and refrain from providing clinical
management recommendations. However, different mathematical al-
gorithms are used and computer analysis is based on different interpre-
tation guidelines.
Published research evaluating these systems is still relatively scarce.
Computer analysis has been compared with that of experts and has
generally yielded satisfactory results [63–67]. Comparisons between
the systems are difﬁcult as different numbers of observers and different
observer experiences were selected. A small number of studies have
evaluated the capacity of computer alerts to predict adverse neonatal
outcomes [68–70]. The results suggest that it is possible to achieve
a good prediction of newborn acidemia with computer analysis of
CTG tracings acquired shortly before birth. Again, comparisons between
studies are hampered by different case selection criteria and differ-
ent choices of adverse neonatal outcome. Studies with larger sam-
ple sizes and direct comparisons of the different systems are lacking.
Two of these systems have recently completed multicenter RCTs com-
paring them with standard CTG analysis [71,72], and their results are
expected soon.
Computer analysis of intrapartum fetal monitoring signals is a
relatively new but promising technology since optimization of the
analysis algorithms will most likely continue. Currently, this tech-
nology should be used with caution as further research is necessary to
evaluate its capacity to detect fetal hypoxia/acidosis and to prevent ad-
verse outcomes.6. Conclusion
There is still much uncertainty regarding the use of the different ad-
junctive technologies in intrapartum fetalmonitoring. FSS is easy to per-
form and can be useful when reduced variability is the main CTG
feature, as the appearance of accelerations and a change to a normal pat-
tern is very predictive of absent hypoxia/acidosis. However, the beneﬁts
of this technique have not been evaluated in randomized trials and
therefore little is known about how it affects neonatal outcome or
intervention rates. FBSmay reduce the incidence of operative deliveries,
although the level of evidence for this is moderate and there is no evi-
dence that fetal outcomes are improved. CTG + ST monitoring results
in a lower need for FBS and perhaps in a modest reduction in operative
deliveries. There is conﬂicting evidence as to whether it improves peri-
natal outcome. Computer analysis provides a reproducible and quantiﬁ-
able approach to CTG and CTG + ST interpretation. It is a promising
method to evaluate how different features/patterns relate to fetal out-
come and perhaps to prompt healthcare professionals to act upon cer-
tain ﬁndings. Further studies are needed to compare the different
computer systems and to evaluate how this technology affects interven-
tion and adverse outcome rates.
Some experts consider that a better understanding of the patho-
physiology of the fetal response to reduced oxygenation during labor
is the main requisite for intrapartum fetal monitoring and, when repet-
itive decelerations occur, the presence of a stable baseline and normal
variability obviates the need for adjunctive technologies and reduces
the false positive rate of CTGs. However, adjunctive technologies will
still need to be considered in the remaining cases.
Further research and development is needed in this ﬁeld to remove
the uncertainty that surrounds many of these adjunctive technologies
and to provide more robust evidence on how they affect intervention
and adverse outcome rates.Conﬂict of interest
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